Findings from Abraxis BioScience’s phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO
Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol …
Read more on News-Medical-Net